昂利康(002940.SZ):與海西聯合藥業簽訂合作開發合同及補充合同
格隆匯 8 月 6日丨昂利康(002940.SZ)公佈,公司(“甲方”)於2020年8月5日與福建海西聯合藥業有限公司(“海西藥業”或者“乙方”)簽訂了《合作開發合同》及《合作開發合同之補充合同》。
公司和海西藥業已就開展七氟烷和地氟烷兩個製劑產品的聯合研發和註冊申報等方面的合作事宜進行探討,有關事項詳見《浙江昂利康製藥股份有限公司説明公告》,雙方同意在充分溝通的基礎上,對七氟烷吸入劑和地氟烷吸入劑項目(“本項目”,七氟烷吸入劑、地氟烷吸入劑合稱為“本項目產品”)進行聯合研發,進一步共同開發研製製劑的生產工藝並申報相應的藥品批文。依據《中華人民共和國合同法》及相關法律法規的規定,經協商一致,雙方同意簽訂《合作開發合同》及《合作開發合同之補充合同》。
雙方將按合同及補充合同的約定共同合作對七氟烷吸入劑、地氟烷吸入劑按照化學藥品註冊分類4類進行研發,並取得七氟烷吸入劑、地氟烷吸入劑的生產批件,將本項目產品投入生產,進行市場銷售。
甲方主要負責產品的註冊申報(獲得註冊批件)、市場銷售;乙方主要負責產品研發、生產。
截止目前,七氟烷吸入劑和地氟烷吸入劑均已在中國境內上市銷售,其中七氟烷吸入劑的國內生產廠家主要為上海恆瑞醫藥有限公司、魯南貝特製藥有限公司和河北一品製藥股份有限公司等,地氟烷吸入劑的國內生產廠家主要為上海恆瑞醫藥有限公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.